Premium
Serum levels of Midkine in children and adolescents without malignant disease
Author(s) -
Lucas Susanne,
Henze Günter,
Schnabel Dirk,
Barthlen Winfried,
Sakuma Sadatoshi,
Kurtz Andreas,
Driever Pablo Hernáiz
Publication year - 2010
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.2009.02885.x
Subject(s) - medicine , midkine , short stature , disease , obesity , cancer , diabetes mellitus , gastroenterology , population , malignant disease , endocrinology , growth factor , receptor , environmental health
Background: Midkine (MK), a heparin‐binding growth factor, is a secreted protein and can be detected in a patient's sera. Method: MK was studied in the sera of 215 children and adolescents without malignant disease using an enzyme‐linked immunosorbent assay in order to determine the distribution of concentrations in a control population for pediatric oncology patients. Tested subjects either underwent surgical procedures or suffered from endocrinological diseases. Results: Elevated MK levels were found in patients with short stature, diabetes mellitus, obesity, and cleft lip and palate. These patients were subsequently excluded from the “non‐cancer” group. MK serum levels did neither correlate with sex, age, weight or height nor showed a normal distribution ( n = 152, range: 0.0–5.58 ng/ml, median: 0.0 ng/ml, mean: 0.26 ng/ml, SD: ±0.61). Conclusion: MK serum values in children and adolescents are widely spread and not normally distributed. The present results indicate that the MK expression is influenced by many factors apart from cancer, which have not yet been identified.